Chlorothiazide is a substrate for the human uptake transporters OAT1 and OAT3

Journal of Pharmaceutical Sciences

Volumn 102, Issue 5, 2013, Pages 1683-1687

  Juhász, Viktória ^a   Beéry, Erzsébet ^a   Nagy, Zoltán ^a   Bui, Annamária ^a   Molnár, Éva ^a   Zolnerciks, Joseph Krisjanis ^a   Magnan, Rémi ^a   Jani, Márton ^a   Krajcsi, Peter ^a  

^a SOLVO BIOTECHNOLOGY   (Hungary)

Author keywords

Chlorothiazide; Diclofenac; Drug interactions; Drug transport; Furosemide; Organic anion transporter; Probenecid; Renal metabolism; Renal transport

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHLOROTHIAZIDE; DICLOFENAC; FUROSEMIDE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PROBENECID;

ANIMAL CELL; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CHO CELL; DRUG PROTEIN BINDING; DRUG UPTAKE; HUMAN; HUMAN CELL; KIDNEY EPITHELIUM; KIDNEY PROXIMAL TUBULE; MAMMAL CELL; MICHAELIS CONSTANT; NONHUMAN; PROTEIN EXPRESSION;

EID: 84876307209     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23491     Document Type: Article

References (22)

1. Osman MA, Patel RB, Irwin DS, Craig WA, Welling PG. 1982. Bioavailability of chlorothiazide from 50, 100, and 250 mg solution doses. Biopharm Drug Dispos 3(2):89-94.
2. Adebayo GI, Mabadeje AF. 1985. Chlorothiazide absorption in humans-Possible example of Michaelis-Menten kinetics. Pharmacology 31(4):181-188.
3. Flaten GE, Dhanikula AB, Luthman K, Brandl M. 2006. Drug permeability across a phospholipid vesicle based barrier: A novel approach for studying passive diffusion. Eur J Pharm Sci 27(1):80-90.
4. Straughn AB, Melikian AP, Meyer MC. 1979. Bioavailability of chlorothiazide tablets in humans. J Pharm Sci 68(9):1099-1102.
5. Brettell HR, Aikawa JK, Gordon GS. 1960. Studies with chlorothiazide tagged with radioactive carbon (C14) in human beings. Arch Intern Med 106:57-63.
6. Beery E, Rajnai Z, Abonyi T, Makai I, Bansaghi S, Erdo F, Sziraki I, Heredi-Szabo K, Kis E, Jani M, Marki-Zay J, Toth KG, Krajcsi P. 2012. ABCG2 modulates chlorothiazide permeability in vitro-Characterization of its interactions. Drug Metab Pharmacokinet 27(3):349-353.
7. Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, Russel FG, Masereeuw R. 2008. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73(2):220-225.
8. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. 2001. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59(5):1277-1286.
9. Hosoyamada M, Sekine T, Kanai Y, Endou H. 1999. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol 276(1 Pt 2):F122-F128.
10. Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Giacomini KM. 2006. The human organic anion transporter 3 (OAT3; SLC22A8): Genetic variation and functional genomics. Am J Physiol Renal Physiol 290(4):F905-F912.
11. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T, Endou H. 2004. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 308(3):1021-1029.
12. FDA-Guidance. Accessed 02/25/2013, at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
13. Hardman JG, Limbird LE, Gilman AG, Eds. 2001. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw Hill.
14. Selen A, Amidon GL, Welling PG. 1982. Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci 71(11):1238-1242.
15. Pea F. 2005. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol 147:35-46.
16. Brater DC. 1978. Increase in diuretic effect of chlorothiazide by probenecid. Clin Pharmacol Ther 23(3):259-265.
17. Uwai Y, Saito H, Hashimoto Y, Inui KI. 2000. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther 295(1):261-265.
18. Bakhiya A, Bahn A, Burckhardt G, Wolff N. 2003. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 13(5):249-256.
19. Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T, Endou H. 2003. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 63(1):143-155.
20. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. 2009. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 106(25):10338-10342.
21. Greenberg A. 2000. Diuretic complications. Am J Med Sci 319(1):10-24.
22. Huen SC, Goldfarb DS. 2007. Adverse metabolic side effects of thiazides: Implications for patients with calcium nephrolithiasis. J Urol 177(4):1238-1243.